New antiangiogenic strategies for the treatment of proliferative synovitis

Expert Opinion on Investigational Drugs

Volumn 14, Issue 1, 2005, Pages 1-17

  Lainer, Dahlia T ^a   Brahn, Ernest ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

v 3; AGM 1470; Angiogenesis; Angiopoietin; Angiostatin; Avastin; Bevacizumab; Cyclooxygenase; Endostatin; Fibroblast growth factor; Hypoxia; Integrin; LM 609; Metalloproteinases; Neovascularisation; Paclitaxel; PPI 2458; Proliferative synovitis; PTK 787; Rheumatoid arthritis; Synovium; Taxol; Thalidomide; TNP 470; VEGF; Vitaxin

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; ANGIOGENESIS INHIBITOR; ANGIOPOIETIN; ANGIOSTATIN; BEVACIZUMAB; CC 1069; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ENDOSTATIN; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; FUMAGILLOL CHLOROACETYLCARBAMATE; GAMMA INTERFERON; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; MATRIX METALLOPROTEINASE; MONOCLONAL ANTIBODY LM 609; PACLITAXEL; PPI 1470; PPI 2458; PROSTAGLANDIN E1; PROSTAGLANDIN E2; SALAZOSULFAPYRIDINE; THALIDOMIDE; TISSUE INHIBITOR OF METALLOPROTEINASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VATALANIB; VIRUS VECTOR; VITRONECTIN RECEPTOR;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; CLINICAL FEATURE; CLINICAL TRIAL; CORRELATION ANALYSIS; DRUG MECHANISM; DRUG TARGETING; GENE TARGETING; HUMAN; HYPOXEMIA; NEUROTOXICITY; NONHUMAN; PANNUS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; SYNOVITIS; SYNOVIUM; VIRAL GENE DELIVERY SYSTEM;

ANGIOGENESIS INHIBITORS; ANIMALS; DRUGS, INVESTIGATIONAL; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; SYNOVITIS;

EID: 12744279878     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.14.1.1     Document Type: Review

References (169)

1. FOLKMAN J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. (1995) 1(1):27-31.
2. NAGASHIMA M, ASANO G, YOSHINO S: Imbalance in production between vascular endothelial growth factor and endostatin in patients with rheumatoid arthritis. J. Rheumatol. (2000) 27 10):2339-2342.
3. FOX RI, KANG H: Structure and function of synoviocytes: In: Arthritis and Allied Conditions (Volume 1). D McCarty, W Koopman (Eds), Lea & Febiger, Philadelphia, PA, USA (1993):263-278.
4. PALEOLOG EM, MIOTLA JM: Angiogenesis in arthritis: role in disease pathogenesis and as a potential therapeutic target. Angiogenesis (1998) 2(4):295-307.
5. COLVILLE-NASH PR, SCOTT DL: Angiogenesis and rheumatoid arthritis: pathogenic and therapeutic implications. Ann. Rheum. Dis. (1992) 51(7):919-925.
6. WALSH DA: Angiogenesis and arthritis. Rheumatology (1999) 38(2):103-112.
7. STEVENS CR, BLAKE DR, MERRY P, REVELL PA, LEVICK JR: A comparative study by morphometry of the microvasculature in normal and rheumatoid synovium. Arthritis Rheum. (1991) 34 12):1508-1513.
8. ARSENAULT AL, LHOTAK S, HUNTER WL, BANQUERIGO ML, BRAHN E: Taxol involution of collagen-induced arthritis: ultrastructural correlation with the inhibition of synovitis and neovascularisation. Clin. Immunol. Immunopathol. (1998) 86(3):280-289.
9. TAYLOR PC: VEGF and imaging of vessels in rheumatoid arthritis. Arthritis Res (2002) 4(Suppl. 3):S99-S107.
10. ROONEY M, CONDELL D, QUINLAN W et al.: Analysis of the histologic variation of synovitis in rheumatoid arthritis. Arthritis Rheum. (1988) 31(8):956-963.
11. FRIESEL RE, MacIAG T. Molecular mechanism of angiogenesis: fibroblast growth factor signal transduction. FASEB J. (1995) 9 10):919-925.
12. NABEL EG, YANG ZY, PLAUTZ G et al.: Recombinant fibroblast growth factor-1 promotes intimal hyperplasia and angiogenesis in arteries in vivo. Nature (1993) 362(6423):844-846.
13. COLLIN-OSDOBY P, ROTHE L, BEKKER S, ANDERSON F, HUANG Y, OSDOBY P: Basic fibroblast growth fictor stimulates osteoclast recruitment, development, and bone pit resorption in association with angiogenesis in vivo on the chick chorioallantoic membrane and activates isolated avian osteoclast resorption in vitro. J. Bone Miner. Res. (2002) 17(10):1859-1871.
14. COZZOLINO F, TORCIA M, LUCIBELLO M et al.: Interferon-α and interleukin 2 synergistically enhance basic fibroblast growth factor synthesis and induce release, promoting endothelial cell growth. J. Clin. Invest. (1993) 91(6 ):2504-2512.
15. VOLIN MV, HARLOW LA, WOODS JM et al.: Treatment with sulfasalazine or sulfapyridine, but not 5-aminosalicyclic acid, inhibits basic fibroblast growth factor-induced endothelial cell chemotaxis. Arthritis Rheum. (1999) 42(9):1927-1935.
16. YAMASHITA A, YONEMITSU Y, OKANO S et al.: Fibroblast growth factor-2 determines severity of joint disease in adjuvant-induced arthritis in rats. J. Immunol. (2002) 168(1):450-457.
17. DVORAK HF, BROWN LF, DETMAR M, DVORAK AM: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol. (1995) 146 5):1029-1039.
18. FERRARA N, GERBER HP, LECOUTER J: The biology of VEGF and its receptors. Nat. Med. (2003) 9(6):669-676.
19. VEIKKOLA T, ALITALO K: VEGFs, receptors and angiogenesis. Semin. Cancer Biol. (1999) 9(3):211-220.
20. SHIBUYA M: VEGF-receptor inhibitors for anti-angiogenesis. Nippon Yakurigaku Zasshi (2003) 122(6):498-503.
21. FAVA RA, OLSEN NJ, SPENCER-GREEN G et al.: Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J. Exp. Med. (1994) 180(1):341-346.
22. NAGASHIMA M, YOSHINO S, ISHIWATA T, ASANO G: Role of vascular endothelial growth factor in angiogenesis of rheumatoid arthritis. J. Rheumatol. (1995) 22(9):1624-1630.
23. IKEDA M, HOSODA Y, HIROSE S, OKADA Y, IKEDA E: Expression of vascular endothelial growth factor isoforms and their receptors Flt-1, KDR, and neuropilin-1 in synovial tissues of rheumatoid arthritis. J. Pathol. (2000) 191(4):426-433.
24. BOTTOMLEY MJ, WEBB NJ, WATSON CJ, HOLT PJ, FREEMONT AJ, BRENCHLEY PE: Peripheral blood mononuclear cells from patients with rheumatoid arthritis spontaneously secrete vascular endothelial growth factor (VEGF): specific up-regulation by tumour necrosis factor-α (TNF-α) in synovial fluid. Clin. Exp. Immunol. (1999) 117 1):171-176.
25. FEARON U, GRIOSIOS K, FRASER A et al.: Angiopoietins, growth factors, and vascular morphology in early arthritis. J. Rheumatol. (2003) 30(2):260-268.
26. SMEETS TJ, BARG EC, KRAAN MC, SMITH MD, BREEDVELD FC, TAK PP: Analysis of the cell infiltrate and expression of proinflammatory cytokines and matrix metalloproteinases in arthroscopic synovial biopsies: comparison with synovial samples from patients with end stage, destructive rheumatoid arthritis. Ann. Rheum. Dis. (2003) 62 7):635-638.
27. KOCH AE, HARLOW LA, HAINES GK et al.: Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J. Immunol. (1994) 152(8):4149-4156.
28. GIATROMANOLAKI A, SIVRIDIS E, ATHANASSOU N et al.: The angiogenic pathway 'vascular endothelial growth factor/flk-1 (KDR)-rcceptor' in rheumatoid arthritis and osteoarthritis. J. Pathol. (2001) 194(1):101-108.
29. SEKIMOTO T, HAMADA K, OIKE Y et al.: Effect of direct angiogenesis inhibition in rheumatoid arthritis using a soluble vascular endothelial growth factor receptor 1 chimeric protein. J. Rheumatol. (2002) 29(2):240-245.
30. MOULD AW, TONKS ID, CAHILL MM et al.: Vegfb gene knockout mice display reduced pathology and synovial angiogenesis in both antigen-induced and collagen-induced models of arthritis. Arthritis Rheum. (2003) 48(9):2660-2669.
31. LATOUR F, ZABRANIECKI L, DROMER C, BROUCHET A, DURROUX R, FOURNIE B: Does vascular endothelial growth factor in the rheumatoid synovium predict joint destruction? A clinical, radiological, and pathological study, in 12 patients monitored for 10 years. Joint Bone Spine (2001) 68(6):493-498.
32. MIOTLA J, MacIEWICZ R, KENDREW J, FELDMANN M, PALEOLOG E: Treatment with soluble VEGF receptor reduces disease severity in murine collagen-induced arthritis. Lab. Invest. (2000) 80 8):1195-1205.
33. SONE H, KAWAKAMI Y, SAKAUCHI M et al.: Neutralization of vascular endothelial growth factor prevents collagen-induced arthritis and ameliorates established disease in mice. Biochem. Biophys. Res. Commun. (2001) 281(2):562-568.
34. BERSE B, HUNT JA, DIEGEL RJ et al.: Hypoxia augments cytokine (transforming growth factor-β (TGF-β) and IL-1 -induced vascular endothelial growth factor secretion by human synovial fibroblasts. Clin. Exp. Immunol. (1999) 115(1):176-182.
35. SHWEIKI D, ITIN A, SOFFER D, KESHET E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature (1992) 359(6398):843-845.
36. LEVY NS, CHUNG S, FURNEAUX H, LEVY AP: Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA binding protein HuR. J. Biol. Chem. (1998) 273(11):6417-6423.
37. GIATROMANOLAKI A, SIVRIDIS E, MALTEZOS E et al.: Upregulated hypoxia inducible factor-α and -2α pathway in rheumatoid arthritis and osteoarthritis. Arthritis Res Ther (2003 5 4):R193-R201.
38. PALEOLOG EM, YOUNG S, STARK AC, MCCLOSKEY RV, FELDMANN M, MAINI RN: Modulation of angiogenic vascular endothelial, growth factor by tumor necrosis factor α and interleukin-1 in rheumatoid arthritis. Arthritis Rheum. (1998) 41(7):1258-1265.
39. KLIMIUK PA, SIERAKOWSKI S, FIEDORCZYK M, CHWIECKO J: [Serum tumor necrosis factor α (TNF-α) concentration correlates with soluble adhesion molecules and vascular endothelial growth factor (VEGF) in rheumatoid arthritis]. Przegl. Lek. (2004) 61(2 ):86-89.
40. CANETE JD, PABLOS JL, SANMARTI R et al.: Antiangiogenic effects of anti-tumor necrosis factor α therapy with infliximab in psoriatic arthritis. Arthritis Rheum. (2004) 50(5 ):1636-1641.
41. 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases. Ann. Rheum. Dis. (2002) 61(Suppl. 2):ii96-ii99.
42. ELICEIRI BP, CHERESH DA. The role of αv integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J. Clin. Invest. (1999) 103(9):1227-1230.
43. 3 as a therapeutic target for blocking tumor-induced angiogenesis. Curr. Drug Targets (2003) 4 2):123-131.
44. 3 for angiogenesis. Science (1994) 264 5158):569-571.
45. JOHNSON BA, HAINES GY, HARLOW LA, KOCH AE: Adhesion molecule expression in human synovial tissue. Arthritis Rheum. (1993) 36 2):137-146.
46. SURI C, JONES PF, PATAN S et al.: Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell (1996) 87(7):1171-1180.
47. DAVIS S, ALDRICH TH, JONES PF et al.: Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell (1996) 87(7):1161-1169.
48. MAISONPIERRE PC, SURI C, JONES PF et al.: Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science (1997) 277(5322):55-60.
49. UCHIDA T, NAKASHIMA M, HIROTA Y, MIYAZAKI Y, TSUKAZAKI T, SHINDO H: Immunohistochemical localisation of protein tyrosine kinase receptors Tie-1 and Tie-2 in synovial tissue of rheumatoid arthritis: correlation with angiogenesis and synovial proliferation. Ann. Rheum. Dis. (2000) 59(8):607-614.
50. DEBUSK LM, CHEN Y, NISHISHITA T, CHEN J, THOMAS JW, LIN PC: Tie2 receptor tyrosine kinase, a major mediator of tumor necrosis factor α-induced angiogenesis in rheumatoid arthritis. Arthritis Rheum. (2003) 48(9):2461-2471.
51. GRAVALLESE EM, PETTIT AR, LEE R et al.: Angiopoietin-1 is expressed in the synovium of patients with rheumatoid arthritis and is induced by tumour necrosis factor α. Ann. Rheum. Dis. (2003 62 2):100-107.
52. SHAHRARA S, VOLIN MV, CONNORS MA, HAINES GK, KOCH AE: Differential expression of the angiogenic Tie receptor family in arthritic and normal synovial tissue. Arthritis Res. (2002) 4 3):201-208.
53. SCOTT BB, ZARATIN PF, COLOMBO A, HANSBURY MJ, WINKLER JD, JACKSON JR: Constitutive expression of angiopoietin-1 and -2 and modulation of their expression by inflammatory cytokines in rheumatoid arthritis synovial fibroblasts. J. Rheumatol. (2002) 29 2):230-239.
54. TAKAHARA K, IIOKA T, FURUKAWA K et al.: Autocrine/paracrine role of the angiopoietin-1 and -2/Tie2 system in cell proliferation and chemotaxis of cultured fibroblastic synoviocytes in rheumatoid arthritis. Hum. Pathol. (2004) 35(2):150-158.
55. SEMENZA GL: Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer (2003) 3(10):721-732.
56. JIANG BH, RUE E, WANG GL, ROE R, SEMENZA GL: Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J. Biol. Chem. (1996) 271(30):17771-17778.
57. DISTLER K: [Hypoxia and angiogenesis in rheumatic diseases]. Z. Rheumatol. (2003) 62(Suppl. 2):II43-II45.
58. LIU LX, LU H, LUO Y et al.: Stabilization of vascular endothelial growth factor mRNA by hypoxia-inducible factor 1. Biochem. Biophys. Res. Commun. (2002) 291(4):908-914.
59. HARA S, KOBAYASHI C, IMURA N: Nuclear localization of hypoxia-inducible factor-2α in bovine arterial endothelial cells. Mol. Cell. Biol. Res. Commun. (1999) 2(2):119-123.
60. HOLLANDER AP, CORKE KP, FREEMONT AJ, LEWIS CE: Expression of hypoxia-inducible factor 1α by macrophages in the rheumatoid synovium: implications for targeting of therapeutic genes to the inflamed joint. Arthritis Rheum. (2001) 44(7):1540-1544.
61. JACKSON JR, MINTON JA, HO ML, WEI N, WINKLER JD: Expression of vascular endothelial growth factor in synovial fibroblasts is induced by hypoxia and interleukin 1β. J. Rheumatol. (1997) 24 7):1253-1259.
62. PETERS CL, MORRIS CJ, MAPP PI, BLAKE DR, LEWIS CE, WINROW VR: The transcription factors hypoxia-inducible factor 1α and Ets-1 colocalize in the hypoxic synovium of inflamed joints in adjuvant-induced arthritis. Arthritis Rheum. (2004) 50(1):291-296.
63. YEO EJ, CHUN YS, CHO YS et al.: YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J. Natl. Cancer Inst. (2003) 95(7):516-525.
64. YEO EJ, CHUN YS, PARK JW: New anticancer strategies targeting HIF-1. Biochem. Pharmacol. (2004) 68(6):1061-1069.
65. MARTEL-PELLETIER J, PELLETIER JP, FAHMI H: Cyclooxygenase-2 and prostaglandins in articular tissues. Semin. Arthritis Rheum. (2003) 33(3):155-167.
66. ZICHE M, JONES J, GULLINO PM: Role of prostaglandin E1 and copper in angiogenesis. J. Natl. Cancer Inst. (1982) 69 2):475-482.
67. 2 and angiogenesis. Proc. Soc. Exp. Biol. Med. (1983) 172(2):214-218.
68. JONES MK, WANG H, PESKAR BM et al.: Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat. Med. (1999) 5(12):1418-1423.
69. MAJIMA M, ISONO M, IKEDA Y et al.: Significant roles of inducible cyclooxygenase (COX)-2 in angiogenesis in rat sponge implants. Jpn. J. Pharmacol. (1997) 75(2):105-114.
70. TSUJII M, KAWANO S, TSUJI S, SAWAOKA H, HORI M, DUBOIS RN: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell (1998) 93(5):705-716.
71. 3 integrin-mediated and Cdc42 /Rac-dependent endothelial-cell spreading, migration and angiogenesis. Nat. Med. (2001) 7 9):1041-1047.
72. 3-dependent endothelial cell adhesion, rac-activation, and spreading through cAMP /PKA-dependent signaling. J. Biol. Chem. (2002) 277(48 ):45838-45846.
73. BEN AV P, CROFFORD LJ, WILDER RL, HLA T. Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS Lett. (1995) 372(1):83-87.
74. WOODS JM, MOGOLLON A, AMIN MA, MARTINEZ RJ, KOCH AE: The role of COX-2 in angiogenesis and rheumatoid arthritis. Exp. Mol. Pathol. (2003) 74(3):282-290.
75. KATORI M, MAJIMA M, HARADA Y: Possible background mechanisms of the effectiveness of cyclooxygenase-2 inhibitors in the treatment of rheumatoid arthritis. Inflamm. Res. (1998) 47(Suppl. 2):S107-S111.
76. KONTTINEN YT, AINOLA M, VALLEALA H et al.: Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis. Ann. Rheum. Dis. (1999) 58(11):691-697.
77. NAGASE H, BREW K: Designing TIMP (tissue inhibitor of metalloproteinases) variants that are selective metalloproteinase inhibitors. Biochem. Soc. Symp. (2003) (70):201-212.
78. JACKSON C: Matrix metalloproteinases and angiogenesis. Curr. Opin. Nephrol. Hypertens. (2002) 11(3):295-299.
79. MOSES MA: The regulation of neovascularization of matrix metalloproteinases and their inhibitors. Stem Cells (1997) 15 3):180-189.
80. JACKSON CJ, ARKELL J, NGUYEN M: Rheumatoid synovial endothelial cells secrete decreased levels of tissue inhibitor of MMP (TTMP1). Ann. Rheum. Dis. (1998) 57(3):158-161.
81. KOLB C, MAUCH S, KRAWINKEL U, SEDLACEK R: Matrix metalloproteinase-19 in capillary endothelial cells: expression in acutely, but not in chronically, inflamed synovium. Exp. Cell Res. (1999) 250(1):122-130.
82. FRASER A, FEARON U, REECE R, EMERY P, VEALE DJ: Matrix metalloproteinase 9, apoptosis, and vascular morphology in early arthritis. Arthritis Rheum. (2001) 44(9):2024-2028.
83. CHAKRABORTI S, MANDAL M, DAS S, MANDAL A, CHAKRABORTI T: Regulation of matrix metalloproteinases: an overview. Mol. Cell. Biochem. (2003) 253(1-2):269-285.
84. PARK CC, MOREL JC, AMIN MA, CONNORS MA, HARLOW LA, KOCH AE: Evidence of IL-18 as a novel angiogenic mediator. J. Immunol. (2001) 167(3):1644-1653.
85. STRIETER RM, POLVERINI PJ, KUNKEL SL et al.: The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J. Biol. Chem. (1995) 270(45):27348-27357.
86. VOLIN MV, WOODS JM, AMIN MA, CONNORS MA, HARLOW LA, KOCH AE: Fractalkine: a novel angiogenic chemokine in rheumatoid arthritis. Am. J. Pathol. (2001) 159(4):1521-1530.
87. KOCH AE: Angiogenesis as a target in rheumatoid arthritis. Ann. Rheum. Dis. (2003) 62(Suppl. 2):ii60-ii67.
88. O'REILLY MS, HOLMGREN L, SHING Y et al.: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell (1994) 79(2):315-328.
89. CAO Y, CAO R, VEITONMAKI N: Kringle structures and antiangiogenesis. Curr. Med. Chem. Anti-Canc. Agents (2002) 2 6):667-681.
90. KIM JM, HO SH, PARK EJ et al.: Angiostatin gene transfer as an effective treatment strategy in murine collagen-induced arthritis. Arthritis Rheum. (2002) 46(3):793-801.
91. KATO K, MIYAKE K, IGARASHI T, YOSHINO S, SHIMADA T: Human immunodeficiency virus vector-mediated intra-articular expression of angiostatin inhibits progression of collagen-induced arthritis in mice. Rheumatol. Int. (2004) (In Press).
92. SUMARIWALLA PF, CAO Y, WU HL, FELDMANN M, PALEOLOG EM: The angiogenesis inhibitor protease-activated kringles 1-5 reduces the severity of murine collagen-induced arthritis. Arthritis Res. Ther. (2003) 5(1):R32-R39.
93. O'REILLY MS, BOEHM T, SHING Y et al.: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell (1997) 88(2):277-285.
94. DIXELIUS J, CROSS MJ, MATSUMOTO T, CLAESSON-WELSH L: Endostatin action and intracellular signaling: β-catenin as a potential target? Cancer Lett. (2003) 196(1):1-12.
95. MATSUNO H, YUDOH K, UZUKI M et al.: Treatment with the angiogenesis inhibitor endostatin: a novel therapy in rheumatoid arthritis. J. Rheumatol. (2002) 29(5):890-895.
96. YIN G, LIU W, AN P et al.: Endostatin gene transfer inhibits joint angiogenesis and pannus formation in inflammatory arthritis. Mol. Ther. (2002) 5(5 Pt 1):547-554.
97. KUROSAKA D, YOSHIDA K, YASUDA J et al.: Inhibition of arthritis by systemic administration of endostatin in passive murine collagen induced arthritis. Ann. Rheum. Dis. (2003) 62 7):677-679.
98. YUE L, WANG H, LIU LH, SHEN YX, WEI W: Anti-adjuvant arthritis of recombinant human endostatin in rats via inhibition of angiogenesis and proinflammatory factors. Acta Pharmacol. Sin. (2004) 25(9):1182-1185.
99. CHILLEMI F, FRANCESCATO P, RAGG E, CATTANEO MG, POLA S, VICENTINI L: Studies on the structure-activity relationship of endostatin: synthesis of human endostatin peptides exhibiting potent antiangiogenic activities. J. Med. Chem. (2003) 46 19):4165-4172.
100. JIMENEZ B, VOLPERT OV, CRAWFORD SE, FEBBRAIO M, SILVERSTEIN RI, BOUCK N: Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat. Med. (2000) 6 1):41-48.
101. KOCH AE, SZEKANECZ Z, FRIEDMAN J, HAINES GK, LANGMAN CB, BOUCK NP: Effects of thrombospondin-1 on disease course and angiogenesis in rat adjuvant-induced arthritis. Clin. Immunol. Immunopathol. (1998) 86(2):199-208.
102. 3-specific humanized mAb. Proc. Natl. Acad. Sci. USA (1998) 95(11):6037-6042.
103. VAN DER ZR, MUROHARA T, PASSERI J, KEARNEY M, CHERESH DA, ISNER JM: Reduced intimal thickening following α(v)β3 blockade is associated with smooth muscle cell apoptosis. Cell Adhes. Commun. (1998) 6(5):371-379.
104. 3 to adhere to lymph node vitronectin. J. Clin. Invest. (1992) 90 4):1406-1413.
105. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell (1994) 79(7):1157-1164.
106. 3 prevents maturation of blood vessels during embryonic neovascularization. J. Cell Sci. (1995) 108 (Pt 7):2655-2661.
107. 3 blocks human breast cancer growth and angiogenesis in human skin. J. Clin. Invest. (1995) 96 4):1815-1822.
108. 3. Clin Cancer Res. (2000) 6 8):3056-3061.
109. 3 antagonist. J. Clin. Invest. (1999) 103 1):47-54.
110. 3 (vitronectin receptor) antagonist, in rat adjuvant-induced arthritis. Arthritis Rheum. (2001) 44(1):128-137.
111. 3), reduces neointimal hyperplasia and total vessel area after balloon injury in hypercholesterolemic rabbits. Circ. Res. (1999) 84 11):1268-1276.
112. HYNES RO: A reevaluation of integrins as regulators of angiogenesis. Nat. Med. (2002) 8(9):918-921.
113. ADAMS JD, FLORA KP, GOLDSPIEL BR, WILSON JW, ARBUCK SG, FINLEY R: Taxol: a history of pharmaceutical development and current pharmaceutical concerns. J. Natl. Cancer Inst. Monogr (1993)(15):141-147.
114. OLIVER SJ, BANQUERIGO ML, BRAHN E: Suppression of collagen-induced arthritis using an angiogenesis inhibitor, AGM-1470, and a microtubule stabilizer, taxol. Cell. Immunol. (1994) 157 1):291-299.
115. BRAHN E, TANG C, BANQUERIGO ML: Regression of collagen-induced arthritis with taxol, a microtubule stabilizer. Arthritis Rheum. (1994) 37(6):839-845.
116. HUI A, KULKARNI GV, HUNTER WL, MCCULLOCH CA, CRUZ TF: Paclitaxel selectively induces mitotic arrest and apoptosis in proliferating bovine synoviocytes. Arthritis Rheum. (1997) 40 6):1073-1084.
117. KUROSE A, YOSHIDA W, YOSHIDA M, SAWAI T: Effects of paclitaxel on cultured synovial cells from patients with rheumatoid arthritis. Cytometry (2001) 44(4):349-354.
118. YOO WH, BAEK HS: Remission of rheumatoid arthritis with taxol in a patient with breast carcinoma. J. Rheumatol. (2000) 27 6):1572-1573.
119. SCHELLER B, SPECK U, ABRAMJUK C, BERNHARDT U, BOHM M, NICKENIG G: Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation (2004) 110(7):810-814.
120. VOGT F, STEIN A, RETTEMEIER G et al.: Long-term assessment of a novel biodegradable paclitaxel-eluting coronary polylactide stent. Eur. Heart J. (2004) 25(15):1330-1340.
121. GERSHLICK A, DE SCHEERDER I et al.: Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial. Circulation (2004) 109(4):487-493.
122. HONG MK, MINTZ GS, LEE CW et al.: Paclitaxel coating reduces in-stent intimal hyperplasia in human coronary arteries: a serial volumetric intravascular ultrasound analysis from the Asian Paclitaxel-Eluting Stent Clinical Trial (ASPECT). Circulation (2003) 107(4):517-520.
123. STONE GW, ELLIS SG, COX DA et al.: One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation (2004) 109 16):1942-1947.
124. STONE GW, ELLIS SG, COX DA et al.: A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N. Engl. J. Med. (2004) 350(3):221-231.
125. INGBER D, FUJITA T, KISHIMOTO S et al.: Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature (1990) 348(6301):555-557.
126. GRIFFITH EC, SU Z, TURK BE et al.: Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin. Chem. Biol. (1997) 4(6):461-471.
127. PEACOCK DJ, BANQUERIGO ML, BRAHN E: Angiogenesis inhibition suppresses collagen arthritis. J. Exp. Med. (1992) 175 4):1135-1138.
128. PEACOCK DJ, BANQUERIGO ML, BRAHN E: A novel angiogenesis inhibitor suppresses rat adjuvant arthritis. Cell. Immunol. (1995) 160(2):178-184.
129. OLIVER SJ, CHENG TP, BANQUERIGO MI, BRAHN E: Suppression of collagen-induced arthritis by an angiogenesis inhibitor, AGM-1470, in combination with cyclosporin: reduction of vascular endothelial growth factor (VEGF). Cell. Immunol. (1995) 166(2):196-206.
130. DE BANDT M, GROSSIN M, WEBER AJ et al.: Suppression of arthritis and protection from bone destruction by treatment with TNP-470/AGM-1470 in a transgenic mouse model of rheumatoid arthritis. Arhtritis Rheum (2000) 43(9):2056-2063.
131. NAGASHIMA M, TANAKA H, TAKAHASHI H et al.: Study of the mechanism involved in angiogenesis and synovial cell proliferation in human synovial tissues of patients with rheumatoid arthritis using SCID mice. Lab. Invest. (2002) 82(8):981-988.
132. SATCHI-FAINARO R, PUDER M, DAVIES JW et al.: Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat. Med (2004) 10(3):255-261.
133. BERNIER SG, LAZARUS DD, CLARK E et al.: A methionine aminopeptidase-2 inhibitor, PPI-2458, for the treatment of rheumatoid arthritis. Proc. Natl. Acad. Sci. USA (2004) 101 29):10768-10773.
134. BRAHN E, BANQUERIGO ML, SCHOETTLER NR, LEE S: A new angiogenesis inhibitor, PPI-2458: regression of collagen-induced arthritis and prevention of erosions. Arthritis Rheum. (2001) 44 S271.
135. BRAHN E, SCHOETTLER NR, BANQUERIGO ML, THOMPSON CD: Involution of collagen-induced arthritis with an angiogenesis inhibitor PPI-2458. Arthritis Rheum. (2003) 48:S347.
136. WOOD JM, BOLD G, BUCHDUNGER E et al.: PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. (2000) 60(8):2178-2189.
137. DREVS J, HOFMANN I, HUGENSCHMIDT H et al.: Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res. (2000) 60(17):4819-4824.
138. GROSIOS K, WOOD J, ESSER R, RAYCHAUDHURI A, DAWSON J: Angiogenesis inhibition by the novel VEGF receptor tyrosine kinase inhibitor, PTK787/ZK222584, causes significant anti-arthritic effects in models of rheumatoid arthritis. Inflamm. Res. (2004) 53 4):133-142.
139. SOLORZANO CC, BAKER CH, BRUNS CJ et al.: Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Cancer Biother. Radiopharm. (2001) 16 5):359-370.
140. LIN B, PODAR K, GUPTA D et al.: The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res. (2002) 62 17):5019-5026.
141. SCHOENBERGER J, GRIMM D, KOSSMEHL P, INFANGER M, KURTH E, EILLES C: Effects of PTK787/ZK222584, a tyrosine kinase inhibitor, on the growth of a poorly differentiated thyroid carcinoma: an animal study. Endocrinology (2004) 145(3):1031-1038.
142. KLEM J: Current studies with PTK787, an oral inhibitor of vascular endothelial growth factor in colorectal cancer. Clin. Colorectal. Cancer (2003) 3(3):147-149.
143. GOLDBRUNNER RH, BENDSZUS M, WOOD J, KIDERLEN M, SASAKI M, TONN JC: PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization. Neurosurgery (2004) 55(2):426-432.
144. HARTMAN GD, FRALEY ME, BILODEAU MT. Kinase insert domain-containing receptor kinase inhibitors as anti-angiogenic agents. Expert Opin. Investig. Drugs (2002) 11(6):737-745.
145. ELARAJ DM, WHITE DE, STEINBERG SM, HAWORTH L, ROSENBERG SA, YANG JC: A pilot study of antiangiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinoma. J. Immunother. (2004) 27(4):259-264.
146. RINI BI, HALABI S, TAYLOR J, SMALL EJ, SCHILSKY RL: Cancer and Leukemia Group B 90206: a randomized Phase III trial of interferon-α or interferon-α plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin. Cancer Res. (2004) 10(8):2584-2586.
147. SPARANO JA, GRAY R, GIANTONIO B, O'DWYER P, COMIS RL: Evaluating antiangiogenesis agents in the clinic the Eastern Cooperative Oncology Group Portfolio of Clinical Trials. Clin. Cancer Res. (2004) 10(4):1206-1211.
148. YANG JC, HAWORTH L, SHERRY RM et al.: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. (2003) 349(5):427-434.
149. COBLEIGH MA, LANGMUIR VK, SLEDGE GW et al.: A Phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin. Oncol. (2003) 30(5 Suppl. 16):117-124.
150. MILLER KD: E2100: a Phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer. Clin. Breast Cancer (2003) 3(6):421-422.
151. RAMASWAMY B, SHAPIRO CL: Phase II trial of bevacizumab in combination with docetaxel in women with advanced breast cancer. Clin. Breast Cancer (2003) 4(4):292-294.
152. JOHNSON DH, FEHRENBACHER L, NOVOTNY WF et al.: Randomized Phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. (2004) 22(11):2184-2191.
153. SANDLER AB, JOHNSON DH, HERBST RS: Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer. Clin. Cancer Res. (2004) 10(12 Pt 2):4258s-4262s.
154. DIAZ-RUBIO E: New chemotherapeutic advances in pancreatic, colorectal, and gastric cancers. Oncologist (2004) 9 3):282-294.
155. FRUCHT H, STEVENS PD, FOGELMAN DR et al.: Advances in the Genetic Screening, Work-up, and Treatment of Pancreatic Cancer. Curr. Treat Options Gastroenterol. (2004) 7(5):343-354.
156. FIGG WD, KRUGER EA, PRICE DK, KIM S, DAHUT WD: Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer. Invest. New Drugs (2002) 20(2):183-194.
157. AGUAYO A: The role of angiogenesis in the biology and therapy of myelodysplastic syndromes. Curr. Hematol. Rep. (2004) 3 3):184-191.
158. LIST AF: New approaches to the treatment of myelodysplasia. Oncologist (2002) 7(Suppl. 1):39-49.
159. HURWITZ H, FEHRENBACHER L, NOVOTNY W et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. (2004) 350(23 ):2335-2342.
160. KABBINAVAR F, HURWITZ HI, FEHRENBACHER L et al.: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. (2003) 21(1):60-65.
161. D'AMATO RJ, LOUGHNAN MS, FLYNN E, FOLKMAN J: Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA (1994) 91(9):4082-4085.
162. CORRAL LG, HASLETT PA, MULLER GW et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α. J. Immunol. (1999) 163(1):380-386.
163. OLIVER SJ, CHENG TP, BANQUERIGO ML, BRAHN E: The effect of thalidomide and 2 analogs on collaggn induced arthritis. J. Rheumatol. (1998) 25(5):964-969.
164. HAUSCHILD A, KROEGER H, MITCHISON NA, UGRINOVIC S, ZWINGENBERGER K: Thalidomide therapy of established collagen-induced arthritis (CIA) not accompanied by an evident Th2 shif. Clin. Exp. Immunol. (1997) 108(3):428-431.
165. OLIVER SJ, FREEMAN SL, CORRAL LG, OCAMPO CJ, KAPLAN G: Thalidomide analogue CC1069 inhibits development of rat adjuvant arthritis. Clin. Exp. Immunol. (1999) 118(2):315-321.
166. KROGER H, MIESEL R, DIETRICH A, OHDE M, RAJNAVOLGYI E, OCKENFELS H: Synergistic effects of thalidomide and poly (ADP-ribose) polymerase inhibition on Type II collagen-induced arthritis in mice. Inflammation (1996) 20(2):203-215.
167. HUIZINGA TW, DIJKMANS BA, VAN DER VELDE EA, VAN DE POUW KRAAN TC, VERWEIJ CL, BREEDVELD FC: An open study of pentoxyfylline and thalidomide as adjuvant therapy in the treatment of rheumatoid arthritis. Ann. Rheum. Dis. (1996) 55(11):833-836.
168. GUTIERREZ-RODRIGUEZ O: Thalidomide. A promising new treatment for rheumatoid arthritis. Arthritis Rheum. (1984) 27 10):1118-1121.
169. GUTIERREZ-RODRIGUEZ O, STARUSTA-BACAL P, GUTIERREZ-MONTES O: Treatment of refractory rheumatoid arthritis-the thalidomide experience. J. Rheumatol. (1989) 16(2):158-163.